Kimberly-Clark expects to close acquisition of Kenvue in the fourth quarter after agreeing to sell brands
Article excerpt
Highlighted: the sentence this signal was extracted from
Reading 4:00 min The European Commission authorized the transaction on the condition that it sells its tampon and other feminine hygiene product brands in the European Economic Area Kimberly-Clark is a global company dedicated to the production and marketing of personal care and hygiene products for consumers, businesses and industries. Photo: REUTERS Published: 10.13.2026 - 20:04 Updated: 10.13.2026 - 20:04 Kimberly-Clark expects to close the acquisition of Kenvue, valued at 48.7 billion dollars, during the fourth quarter of 2026, after the European Commission authorized the transaction on the condition that it sells its tampon and other feminine hygiene product brands in the European Economic Area (EEA), including Kotex. The conditional authorization is part of the regulatory requirements that the U.S. company must meet to finalize the purchase of Kenvue, a manufacturer of products such as Tylenol, Neutrogena and Listerine. "To address the Commission's preliminary competition concerns, Kimberly-Clark offered to divest all of its tampon brands and other feminine hygiene products in the EEA, including intellectual property rights, know-how, as well as associated key employees and customer relationships," the European Commission stated in a press release. The brands included in the divestment are Kotex, as well as the sub-brands Lidie, Camelia and Record. The European...
Keep reading with a free account
The rest of this article, and every signal for Kimberly-Clark, is in your free account.
